WO2012112511A1 - Inhibiteur de l'absorption du cholestérol (azétidinone) et acides gras oméga 3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction des événements cardiovasculaires - Google Patents

Inhibiteur de l'absorption du cholestérol (azétidinone) et acides gras oméga 3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction des événements cardiovasculaires Download PDF

Info

Publication number
WO2012112511A1
WO2012112511A1 PCT/US2012/025003 US2012025003W WO2012112511A1 WO 2012112511 A1 WO2012112511 A1 WO 2012112511A1 US 2012025003 W US2012025003 W US 2012025003W WO 2012112511 A1 WO2012112511 A1 WO 2012112511A1
Authority
WO
WIPO (PCT)
Prior art keywords
omega
formulation
epa
dha
acid
Prior art date
Application number
PCT/US2012/025003
Other languages
English (en)
Inventor
George Jackowski
Rachelle MACSWEENEY
Nisar Shaikh
Jason Yantha
Valerie SCHINI-KERTH
Original Assignee
Pivotal Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pivotal Therapeutics, Inc. filed Critical Pivotal Therapeutics, Inc.
Priority to EP12705588.7A priority Critical patent/EP2675442A1/fr
Priority to CA2827555A priority patent/CA2827555A1/fr
Priority to JP2013554537A priority patent/JP2014505729A/ja
Priority to US13/584,403 priority patent/US8952000B2/en
Priority to PCT/US2012/051103 priority patent/WO2013122624A1/fr
Priority to EP12753303.2A priority patent/EP2814476A1/fr
Publication of WO2012112511A1 publication Critical patent/WO2012112511A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to combinations of one or more cholesterol absorption inhibitors, such as ezetimibe, with mixtures of omega-3 fatty acid compositions designed to mediate omega-3 deficiencies in individuals in need thereof; and to methods of administering such combinations, and to unit dosages of such combinations for the reduction of circulating cholesterol levels in cardiovascular disease patients (CVD).
  • the invention particularly relates to compositions wherein the omega-3 formulation is designed to mediate omega-3 deficiencies in individuals in need thereof; particularly to
  • compositions containing specific ratios of highly purified long chain fatty acid are provided.
  • compositions which are effective in elevating omega-3 levels to a point at which the risk factors for cardiovascular disease are mitigated, and most particularly to a composition having an EPA:DHA ratio and level of omega-3 purity which enable them to be effective in providing a sustained vasodilatory effect, defined as a vasodilatory effect lasting at least 6 hours.
  • Cardiovascular disease represents the primary cause of mortality for men and women in developed countries globally. These premature deaths come at great cost to both the individuals and their families, as well as representing a huge burden to the health care system of the country.
  • the risk factors for coronary heart disease are well- recognized and include: higher than average serum cholesterol, elevated levels of LDL; a low level of HDL in proportion to the LDL level; higher than average serum triglycerides; and higher levels of lipid oxidation products creating plaques and streaks which cause blockages of coronary arteries.
  • An additional risk factor for coronary heart disease and stroke is high blood pressure. Reduction in these risk factors is effective to reduce the prevalence of coronary heart disease and its many costs.
  • cholesterol and triglycerides are part of the total lipoprotein complexes present in the bloodstream, characterized as high-density lipoprotein (HDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and very-low- density lipoprotein (VLDL) fractions.
  • HDL high-density lipoprotein
  • IDL intermediate-density lipoprotein
  • LDL low-density lipoprotein
  • VLDL very-low- density lipoprotein
  • VLDL VLDL
  • High levels of total cholesterol (total-C), LDL-C, and apolipoprotein B (a membrane complex for LDL-C) promote human atherosclerosis and decreased levels of HDL-C and its transport complex, apolipoprotein A, which are associated with the development of atherosclerosis.
  • Cardiovascular morbidity and mortality in humans can vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C.
  • Cholesterol absorption inhibitors are known (see for example Rosenblum, S. B., et al., J. Med. Chem., 41(6):973-80 (1998)).
  • CVD incidence poor diet and sedentary lifestyle are major factors that contribute to increased risk for the development, and progression of CVD. Because of this, clinical management of CVD often includes an attempt to modify a patient's lifestyle to increase exercise, and incorporate a balanced diet, rich in omega-3 fatty acids. Due to non-compliance, and often an inability of a patient to adhere to lifestyle modifications, optimal patient care is not achieved through these efforts alone, and other therapeutic interventions or strategies must be considered.
  • Treatment options may include lipid-regulating medications, such as statins, or fibrates that act to lower low density lipoprotein (LDL) cholesterol and/or triglycerides (TG), metabolic components that are thought to contribute to atherosclerotic plaque buildup, and increase the risk for heart attack or stroke.
  • lipid-regulating medications such as statins, or fibrates that act to lower low density lipoprotein (LDL) cholesterol and/or triglycerides (TG), metabolic components that are thought to contribute to atherosclerotic plaque buildup, and increase the risk for heart attack or stroke.
  • Additional therapies may include the use of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol.
  • many of these treatment options come with unwanted side effects that could add additional health risks, or cause physical discomfort.
  • Azetidinone-based compounds e.g. ezetimibe
  • cholesterol absorption inhibitors see Bioorg. Med. Chem., 7(10):2199-202 (1999)).
  • Ezetimibe is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. It is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water.
  • the chemical name is (3R,4S)-l-(p-fluorophenyl)-3-[(3S)-3-(p-fluorophenyl)-3- hydroxypropyl]-4-(p-hydroxyphenyl)-2-azetidinone(6) and the molecular formula is
  • the present invention provides a novel composition, which may be incorporated into an orally administered dietary regimen for the reduction of risk factors associated with CVD.
  • the composition of the invention represents a unique combination of one or more cholesterol absorption inhibitors with an omega 3 fatty acid formulation.
  • omega-3 fatty acid deficient 70% of Americans are omega-3 fatty acid deficient. Further studies indicate that over 84% of CVD patients are deficient in omega-3 fatty acids, specifically Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) and Docosapentaenoic acid (DP A).
  • EPA Eicosapentaenoic acid
  • DHA Docosahexaenoic acid
  • DP A Docosapentaenoic acid
  • Omega-3 fatty acids are natural polyunsaturated fats found in sea foods like fish and which are presently also available as dietary supplements. They contain more than one double bond in the aliphatic chain. They are named according to the number (>1), position and configuration of double bounds.
  • the three major types of omega-3 fatty acids are alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA).
  • omega-3 polyunsaturated fatty acids have been shown to protect against several types of cardiovascular diseases such as myocardial infarction, arrhythmia, atherosclerosis, and hypertension (Abeywardena and Head, 2001 ; Kris-Etherton et al., 2003). It is widely accepted that (EPA) (C20:5n-3) and (DHA) (C22:6n-3) are the major biological active polyunsaturated fatty acids contributing to the prevention of a variety of cardiovascular disorders by improving endothelium-dependent vasodilatation and preventing activation of platelets.
  • a combination therapy including a novel omega-3 formulation in combination with one or more cholesterol absorption inhibitors, could be provided for enhancing the patient's lipid profile and mitigating the various risk factors for
  • cardiovascular disease particularly reduction of overall serum cholesterol levels, reductions in high blood pressure and pulse rate, increase in the HDL:LDL ratio, reduction of triglycerides and homocysteine levels, lowering of the activity of the blood coagulation factor VH-phospholipid complex, and prevention of lipid oxidation and the formation of plaques, a long felt need would be realized.
  • the prior art fails to disclose a pharmaceutical formulation as set forth in the instantly disclosed invention, containing the combination of a cholesterol absorption inhibitor and an omega-3 composition containing about 90% or greater omega 3 fatty acids by weight having a combination of Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA.DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA is about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition.
  • EPA + DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition.
  • each of these components which independently reduce one or more of the risk factors for cardiovascular disease (CVD), are expected to work synergistically to reduce the risk of CVD more effectively than any of these components taken alone.
  • omega-3 fatty acid preparations to cause endothelium-dependent relaxations depends on their relative content of EPA and DHA, as well as the purity of the overall formulation and the presence of additional key omega-3 fatty acids, particularly DPA.
  • the optimization of the ratio of EPA:DHA in omega-3 preparations may provide new products with an enhanced vascular protective potential.
  • the present invention provides a novel composition, which may be incorporated into an orally administered formulation for the reduction of risk factors associated with CVD, and a novel treatment method.
  • a composition of the formulation of the invention may be used orally to treat and/or prevent risk factors of CVD and stroke, including reduction of high blood pressure and improving overall lipid profiles, e.g. low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides. While not wishing to be bound by theory, the inventors believe that the compositions work by acting at different sites and aspects of cardiovascular disease.
  • the compositions of the present invention are preferably presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient.
  • the present invention also provides methods of treatment, for example administering to a patient having an omega-3 fatty acid deficiency, that may be evidencing one or more risk factors for CVD, a therapeutically effective amount of a formulation in accordance with the invention to achieve a therapeutic level of omega-3; whereby mitigation of said one or more risk factors for CVD is achieved.
  • the invention is also a method for providing a sustained vasodilatory effect in a patient by administering a therapeutically effective amount of a formulation in accordance with the invention, whereby an indomethacin-independent sustained vasodilatory effect is achieved.
  • composition of the invention By providing a method of treatment for mediating omega-3 deficiencies, use of the instant invention to improve the health of the heart and to reduce risk factors associated with cardiovascular disease by delivering to an individual the composition of the invention is realized.
  • Delivery of the composition of the invention e.g., by oral administration, has been shown to be useful for preventing oxidation of low density lipoprotein (LDL), increasing high density lipoprotein (HDL), and for reducing total cholesterol. Delivery of the composition of the invention is also useful for reducing triglycerides and reducing homocysteine.
  • LDL low density lipoprotein
  • HDL high density lipoprotein
  • Delivery of the composition of the invention is also useful for reducing triglycerides and reducing homocysteine.
  • compositions of the invention are formulated such that an effective amount is delivered by multiple tablets (or other suitable formulation) a day.
  • these doses may be taken with meals, mixed into food, or taken on an empty stomach. Generally improvement is observed after two to eight weeks of daily use.
  • compositions of the invention may be delivered daily in a suitable form (e.g., a chew or bar).
  • suitable dosage regimens may be readily developed by one of skill in the art. Such dosage regimens are not a limitation of the invention.
  • compositions of the present invention in addition to their use in treating CVD in humans, may also be useful in treating non-human animals, particularly mammals.
  • these dietary supplements may be useful for companion animals such as dogs and cats, for cattle, horses, and pigs, among other animals.
  • a primary objective of the instant invention is to teach a combined therapy comprising a cholesterol absorption inhibitor and an omega-3 fatty acid formulation.
  • the combined therapy may be supplied either as single dosage forms or in a combined dosage form.
  • One or more cholesterol absorption inhibitors are useful in the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, atherosclerotic disease, coronary heart disease (CHD) and cardiovascular disease (CVD).
  • ezetimibes marketed under such trade names as
  • omega-3 fatty acid formulation containing a minimum of 90% omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DP A are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition.
  • EPA + DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition.
  • the fatty acids of the present invention are understood to include
  • biologically active glyceride forms e.g. triglycerides
  • biologically active ester forms e.g. ethyl ester forms
  • biologically active phospholipid forms their derivatives, conjugates, precursors, and pharmaceutically acceptable salts and mixtures thereof. It is understood that the combination of omega-3 formulation and cholesterol absorption inhibitors may be provided as a single unit dosage form, or as separate and distinct unit dosage forms.
  • a further objective of the instant invention is to teach methods of administering such combinations, and unit dosages of such combinations for the treatment of hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, atherosclerotic disease, and vascular disease in cardiovascular disease patients (CVD), wherein by these risk factors are lowered significantly.
  • CVD cardiovascular disease patients
  • Figure 1 illustrates the study design for the VASCAZENTM open label study
  • Figure 2 is a plot of improved whole blood EPA + DHA + DPA levels baseline to week 6;
  • Figure 3 illustrates the normal distribution curves for Groups A-C during the Open Label Study
  • Figure 4 illustrates the effect of differing EPA.DHA ratios on the relaxation of coronary artery rings with and without the presence of the endothelium;
  • Figure 5 discloses the relaxation effect of an EPA:DHA 6:1 control versus the effect of eNOS and EDHF inhibitors;
  • Figure 6 discloses how the presence of Src kinase and PI3 -kinase impacts the relaxation effect of an EPA:DHA 6:1 product
  • Figure 7 illustrates the shift in relaxation effect of an EPA:DHA 6:1 product by membrane permeant analogues
  • Figure 8A illustrates the effect EPA:DHA 6: 1 has on both Akt and eNOS phosphorylation
  • Figure 8B illustrates Western Blot Data Showing Sustained eNOS
  • Figure 9 demonstrates the relation of purity to the sum of EPA + DHA relative to total Omega-3 ratios on the relaxation of coronary artery rings in the presence or absence of endothelium;
  • Figure 10 illustrates that the relaxation effect of the subject EPA:DHA 6: 1 formulation is insensitive to the presence of indomethacin
  • Figure 11A and Figure 1 IB illustrate the indomethacin sensitivity of the relaxation effect of the subject EPA:DHA 6:1 formulation relative to several over the counter Omega-3 products;
  • Figure 12 illustrates the indomethacin sensitivity of the relaxation effect of the EPA:DHA 6:1 formulation relative to a formulation of like ratio containing certain additives
  • Figure 13 illustrates the comparative vasorelaxing effect of EPA:DHA 6:1 according to the present invention as compared to EPA:DHA 1 : 1, EPA alone and DHA alone;
  • Figure 14 illustrates the mechanism by which EPA:DHA 6:1 stimulates the endothelial formation of NO via the redox-sensitive activation of the Phosphoinositide 3- Kinase (PI3 -Kinase)/ Protein Kinase (Akt) pathway.
  • PI3 -Kinase Phosphoinositide 3- Kinase
  • Akt Protein Kinase
  • the present invention provides a combination therapy and a method for its use which contains novel combinations of selected mixtures of one or more cholesterol absorption inhibitors with an omega 3 fatty acid formulation.
  • the methods are useful in the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, atherosclerotic disease, cardiovascular disease (CVD) and vascular disease.
  • compositions of this invention acts to reduce serum cholesterol levels and blood pressure, increase HDL levels in proportion to LDL levels, to protect lipids from oxidation thereby preventing the formation of plaques which block coronary arteries, and to lower both triglyceride levels and homocysteine levels.
  • oral administration of the compositions of this invention acts to reduce the risk of stroke, as well as heart attack, in human adults.
  • One particularly desirable embodiment of the invention is directed toward a composition and a method for its use including a cholesterol absorption inhibitor, which is exemplified by, albeit not limited to an ezetimibe marketed under such trade names as EZEDOCTM, EZEETM, EZETTM, EZETIBTM, EZZICARDTM, LIPEZETTM, ZETICATM, EZTATM, and EZIBLOCTM , or pharmaceutically acceptable salts thereof or a combination thereof; and an omega-3 fatty acid formulation.
  • a cholesterol absorption inhibitor which is exemplified by, albeit not limited to an ezetimibe marketed under such trade names as EZEDOCTM, EZEETM, EZETTM, EZETIBTM, EZZICARDTM, LIPEZETTM, ZETICATM, EZTATM, and EZIBLOCTM , or pharmaceutically acceptable salts thereof or a combination thereof; and an omega-3 fatty acid formulation.
  • the present invention provides a long chain fatty acid composition that includes a formulation containing a minimum of about 90% omega 3 fatty acids by weight having a combination of Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA is about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition.
  • EPA + DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition.
  • the fatty acids of the present invention are understood to include biologically active glyceride forms, e.g. triglycerides, biologically active ester forms, e.g. ethyl ester forms, and biologically active phospholipid forms, their derivatives, conjugates, precursors, and pharmaceutically acceptable salts and mixtures thereof.
  • biologically active glyceride forms e.g. triglycerides
  • biologically active ester forms e.g. ethyl ester forms
  • biologically active phospholipid forms their derivatives, conjugates, precursors, and pharmaceutically acceptable salts and mixtures thereof.
  • the pharmaceutical formulation of the instant invention is contemplated as being administered in amounts providing a daily dosage of 1 to 4 gm of said formulation.
  • the pharmaceutical formulation at such dosage level being effective for the treatment or prophylaxis of risk factors of cardiovascular disease and the protection against sudden death in patients with CVD.
  • Pharmaceutical formulations of the instant invention may be provided wherein a unit form is a gel or liquid capsule.
  • An exemplary unit dosage form includes from about 645 to about 715 mg/gm EPA, for example about 680 mg/gm EPA and from about 105 to 115 mg/gm, for example about 110 mg/gm DHA.
  • the unit dosage can include from about 22 to about 28 mg/gm DP A for example about 25 mg/gm DP A.
  • Unit doses may additionally include a stabilizer, e.g. tocopherol in amounts up to about 0.5 %, for example about 0.15% to about 0.25% or about 0.2% by weight.
  • the effective unit dosage is generally 3 gm to 4 gm of the pharmaceutical formulation which are provided daily to CVD patients in one or more unit doses, for example about 3 - 4 one gram capsules per day.
  • one or more optional ingredients can be included in the formulations. Such ingredients may be separately added or may be components of the source from which the omega 3 fatty acids in the formulation are derived.
  • the formulation may further contain about 30 mg/gm of arachidonic acid (AA). In some embodiments, the formulation may further contain up to about 5%, for example about 3% or about 30 mg/gm of arachidonic acid (AA). It has been discovered that aspirin-acetylated COX-2 is also able to convert Omega-6 AA through lipoxygenases (LOX) to lipoxins (LXs), which are potent anti-inflammatory mediators (Nature Chemical Biology, Vol. 6, June 2010, Pp 401-402).
  • LOX lipoxygenases
  • LXs lipoxins
  • Some embodiments of the formulation contains >2%, for example >3%, of
  • 18 carbon Omega-3 fatty acids either individually or in total.
  • exemplary 18 carbon atom omega-3 fatty acids include alpha-linolenic acid (ALA) and Stearidonic acid (SDA), either alone or in combination.
  • ALA alpha-linolenic acid
  • SDA Stearidonic acid
  • the composition can contain additional fatty acids in lesser amounts, usually less than about 1% of each that is present. Exemplary embodiments contain about 0.3- 0.7%, or about 5% of any of the additional fatty acids,
  • additional fatty acids can include, for example, omega -6 fatty acids such as Dihomo-gamma-linolenic acid (DGLA; 20:3n6), Docosapentaenoic acid (Osbond acid; 22:5n6); omega-9 fatty acids such as Oleic acid (18:ln9) and others such as 7,10,13,15-hexadecatetraenoic acid and (16:4nl), 9,12,15,17-octadecatetraenoic acid (18:4nl ).
  • omega -6 fatty acids such as Dihomo-gamma-linolenic acid (DGLA; 20:3n6), Docosapentaenoic acid (Osbond acid; 22:5n6)
  • omega-9 fatty acids such as Oleic acid
  • Eicosatetraenoic acid (ETA; 20:4n3) may be present in amounts up to about 2%, for example about 1.5%
  • Heneicosapentaenoic acid (HP A; 21 :5n3) may be present in amounts up to about 3%, for example at about 2.3%.
  • These additional fatty acids may be added separately or may be present in formulations obtained from particular sources using particular methods.
  • Other additional components and fatty acids may also be present in small amounts, for example 0-0.25% of the formulation.
  • composition is formulated with a DHA content to provide about 400 mg per daily dose.
  • TG high density phospholipids
  • LDL low density lipoprotein
  • a highly potent omega-3 formulation in accordance with the present invention is marketed by Pivotal Therapeutics, Inc., under the trade name
  • VASCAZENTM to alleviate the cardiovascular risks associated with omega-3 deficiency.
  • VASCAZENTM has been formulated for the dietary management of omega-3 deficiency in patients with CVD, providing EPA and DHA to levels not attainable through normal dietary modifications.
  • the VASCAZENTM product exemplifies the present invention in being composed of about 90% or more omega-3 fatty acids at a ratio of eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) within the range of 5.7: 1 - 6.3: 1, respectively.
  • the formulation contains about 680mg/g of EPA, about 1 l Omg/g of DHA, and about 25 mg/g of DP A per capsule.
  • Each capsule has a total weight of about 1000 mg. It is generally contemplated that a daily regimen of VASCAZENTM includes 4 tablets per day given either in one dose or in separate doses throughout the day. With respect to a 1000 mg fill, the formulation contains at least about 90% or more omega-3 fatty acids, wherein about 80% is the sum of EPA+DHA, and about 82% the sum of EPA + DPA + DHA. Embodiments can also contain about 30mg/g of
  • arachidonic acid an omega-6 fatty acid, and/or >3% of 18 carbon Omega-3 fatty acids.
  • the present invention provides a novel composition, which may be incorporated into an orally administered formulation for the reduction of risk factors associated with CVD, and a novel treatment method.
  • a composition of the formulation of the invention may be used orally to treat and/or prevent risk factors of CVD and stroke, including reduction of high blood pressure and improving overall lipid profiles, e.g. low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides. While not wishing to be bound by theory, the inventors believe that the compositions work by acting at different sites and aspects of cardiovascular disease.
  • the compositions of the present invention are preferably presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient.
  • the daily dose of formulated composition provides a strong antiinflammatory and mood enhancing effect with a specific amount of DHA for the protection against sudden death in patients with CVD.
  • omega-3 deficient due to lack of consumption of this essential nutrient in the typical "western diet", which includes an overabundance of proinflammatory omega-6 fatty acid intake, by comparison.
  • this dietary trend can be particularly dangerous. Coupled with other cardiometabolic risk factors, omega-3 deficiency further exacerbates the chronic progression of this disease.
  • a growing body of evidence has demonstrated the cardiovascular health risks associated with chronic omega-3 deficiency.
  • a dietary deficiency of EPA acid and DHA in particular allows for downward pro-inflammatory pressures created by the metabolism of arachidonic acid (AA) that is typically very high in the diets of most Americans.
  • AA arachidonic acid
  • omega-3 fatty acid deficiency contributes to a pro-inflammatory state, the consequences of which include negative effects on cardiovascular health, including increased risk for development of dyslipidemia (high cholesterol, high triglycerides), atherosclerotic plaque buildup, hypertension, and cardiac arrhythmia.
  • statins that will not interfere with intestinal cholesterol levels
  • VASCAZENTM a protocol as set forth in the Open Label trial discussed herein, in combination with ezetimibe to lower circulating cholesterol concentrations.
  • a second group of patients will be those who are not prescribed ezetimibe as part of their normal course of therapy, but are prescribed VASCAZENTM.
  • a third group will be prescribed ezetimibe alone, with no VASCAZENTM therapy.
  • Blood samples will be taken from all patients at the study baseline. All patients will be fasting for 12 hours prior to the blood sample being taken. After 6 weeks a second blood sample will be taken. This will determine if the drug intervention of ezetimibe alone, VASCAZENTM alone or a combination of ezetimibe and VASCAZENTM influenced the circulating cholesterol concentration.
  • the formulation in accordance with the present invention was generally well tolerated, with only minor adverse events reported in a small proportion of study
  • Subjects were eligible for the study if they met all inclusion and exclusion criteria set out in the clinical study protocol. All eligible subjects provided informed consent prior study enrollment, and entered Group A ( Figure 1.). Sixty three subjects were provided 4 capsules per day of VASCAZENTM (Group B), an oral dose of 2720mg EPA and 440mg DHA per day. After two weeks of treatment, whole blood omega-3 blood level was assessed, and 31 subjects entered into Group C, for continued treatment. Group C subjects provided whole blood samples at weeks 4 and week 6, for follow-up Omega-ScoreTM assessment.
  • the primary outcome measure was the change in Omega-ScoreTM values expressed as a percentage of total blood fatty acid levels over a 2-week period for Group B, and 6-week period for Group C.
  • the baseline Omega-ScoreTM value for Group A was calculated as the mean percentage at week 0, prior to VASCAZENTM intervention, and Groups B and C Omega-ScoreTM means were evaluated at the specified time points accordingly.
  • Fatty acids were extracted from 200 ⁇ , of whole blood sample using a mixture of methanol and chloroform. Fatty acids were then methylated with 10% (w/v) BC1 3 in methanol by incubation at 90 °C for 25 min to form fatty acid methyl esters (FAMEs). After cooling the FAMEs were extracted with water/hexane mixture and 1 uL of n-hexane extract was injected for GC-MS analysis.
  • the safety population was defined as a patient group that had a minimum of 2 weeks and maximum of 6 weeks VASCAZENTM, at a dose of 4 capsules per day.
  • Primary analyses of treatment efficacy was performed on the subset of enrolled study subjects for whom blood measurements were taken at baseline and after 2 weeks of study treatment.
  • the change in blood Omega-ScoreTM levels over the 2-week period (expressed as a percentage change from baseline) was computed for each study subject.
  • the distribution of changes in blood Omega- ScoreTM levels over 2 weeks were tested for normality using the Pearson- D'Agostino test.
  • a paired t-test was conducted in order to test the change in blood Omega-ScoreTM levels over the 2-week period.
  • VASCAZENTM intervention for 2 weeks had a significant (PO.0001)
  • Omega-ScoreTM (%) % of Patients At Risk ( ⁇ 6.1% Omega-
  • VASCAZENTM significantly (PO.0001) increased mean scores from 3.4% to 7.9%, representing a 132.4% improvement, bringing the mean score of the total population to well within the >6.1% low risk quartile. Indeed, only 15% of study participants remained below this benchmark level after 4 weeks, a level that is sustained in the study group through 6 weeks of VASCAZEN intervention.
  • VASCAZEN was generally well tolerated with a low incidence, of minor adverse events that are typical for omega-3 polyunsaturated fatty acid ethyl esters. This study has highlighted the prevalence of chronic omega-3 deficiency in the majority of people (84%), both men and women.
  • omega-3 deficiency in patients with CVD are well documented, with numerous studies linking EPA and DHA deficiency. Many studies and current therapeutic approaches have categorized omega-3 as a
  • EPA and DHA should not be considered therapeutic agents, rather, they should be considered essential nutrients, which should ideally be consumed regularly as part of a healthy balanced diet. Omega-3 deficiency in patients with CVD adds unnecessary risks, which can be avoided with suitable omega-3 supplementation.
  • the present invention as exemplified by VASCAZENTM intervention provides essential balanced levels of EPA and DHA that are difficult for many CVD patients to incorporate into their daily diet through food alone. In the typical western diet, the average American consumes 15 times less omega-3 fatty acids from fish than what is required to attain and maintain clinically beneficial levels of EPA and DHA. In order to consume enough of this essential nutrient to provide the daily dose that the present invention can provide, one would have to eat fish every single day, for more than one meal per day. This is unrealistic for most people.
  • formulations according to the invention have been shown to provide a sustainable eNOS vasodilatory effect, defined as a vasodilatory effect persisting for 6 hours or more, which has heretofore not been achievable with either prescription or OTC grade omega-3 supplements.
  • ROS Reactive oxygen species Reactive Oxygen Species
  • sGC Soluble guanylyl cyclase
  • the endothelium consists of a single endothelial cell layer lining the luminal surface of all blood vessels. Endothelial cells play an important function in the regulation of vascular homeostasis. They regulate the contact of blood with the underlying
  • thrombogenic arterial wall respond to numerous physiological stimuli such as circulating hormones and shear stress by releasing several short-lived potent endothelium- derived vasoactive factors such as nitric oxide (NO) and endothelium- derived
  • EDHF hyperpolarizing factor
  • NO is produced by endothelial nitric oxide synthase (eNOS) from L- arginine, NO plays critical roles in normal vascular biology and pathophysiology. NO induces relaxation of the vascular smooth muscle by activating soluble guanylyl cyclase resulting in the formation of cyclic guanosine 3'-5'monophosphate (cGMP). In addition to the regulation of vascular tone and inhibition of platelet aggregation, NO also inhibits many key steps involved in atherogenesis including vascular smooth muscle cell proliferation, monocyte adhesion (Dimmeler et al., 1997; Hermann et al., 1997; Tsao et al., 1996) and cell death.
  • eNOS endothelial nitric oxide synthase
  • eNOS can be activated by receptor-dependent and -independent agonists as a consequence of an increase in the intracellular concentration of free Ca ([Ca 2+ ]i) and the association of a Ca 2+ / calmodulin (CaM) complex with eNOS leading to its activation (Fleming et al., 2001). Indeed both the agonist-induced NO formation and subsequent vasorelaxation are abolished by the removal of Ca 2+ from the extracellular space as well as by CaM antagonists.
  • eNOS is also regulated in endothelial cells at a post- translational level primarily through protein/protein interactions and multisite
  • eNOS phosphorylation at Serl 16, Thr497, Ser635, and Serl 179
  • Residue numbers are for the bovine sequence, equivalent to Serl 14, Thr495, Ser633, and Serl 177 in the human sequence
  • positive and negative protein modulators such as caveolin (Cav-1) and heat shock protein 90 (Garcia-Cardena et al., 1998; Ju et al., 1997; Pritchard et al., 2001).
  • Akt PI3-kinase-dependent mechanisms
  • Akt one of the major regulatory targets of PI3-kinase, has been shown to directly phosphorylate eNOS at Serl 179 and activate the enzyme in response to vascular endothelial growth factor (VEGF), sphingosine-1 -phosphate, and estrogens (Dimmeler et al., 1997; Fulton et al., 1999).
  • VEGF vascular endothelial growth factor
  • sphingosine-1 -phosphate sphingosine-1 -phosphate
  • estrogens Dimmeler et al., 1997; Fulton et al., 1999.
  • eNOS-Serl l79 can also be phosphorylated by AMP-activated protein kinase (Busse et al., 2002), protein kinase A (PKA), and protein kinase G (PKG). Exactly which protein kinase(s) phosphorylates eNOS-Serl 179 in intact cells appears to be dependent on the type of endothelial cells and stimuli.
  • PKA protein kinase A
  • PKG protein kinase G
  • shear stress phosphorylates eNOS Serl 179 by a PI3-kinase- and PKA-dependent manner without involving Akt whereas EGF phosphorylates eNOS Serl 179 by a PI3-kinase- and Akt-dependent manner (Boo et al., 2002).
  • EGF phosphorylates eNOS Serl 179 by a PI3-kinase- and Akt-dependent manner
  • the ischemia-reperfusion injury activates the PKA pathway leading to the phosphorylation of eNOS at Serl 179 and Ser635 (Li et al., 2010).
  • eNOS expression can be modulated by several factors including shear stress (Butt et al., 2000), hypoxia, low- density lipoproteins (LDL) (Chen et al., 2008; Chen et al., 1999) and oxidized fatty acids (Corson et al., 1996).
  • Endothelium-dependent vasorelaxation has also been observed in some blood vessels following inhibition of NO and PGI2 synthesis and has been attributed to endothelium-derived hyperpolarizing factor (EDHF).
  • EDHF relaxes blood vessels through hyperpolarization of the vascular smooth muscle. This effect will close voltage-operated Ca channels resulting in reduction of the intracellular free Ca level and subsequent relaxation of the vascular smooth muscle. Potassium (K + ) channels underlie the
  • endothelial dysfunction hyperpolarization induced by EDHF and involve intermediate conductance Ca 2+ -activated K + (IKCa) channels and small conductance Ca 2+ -activated K + (SKCa channels).
  • IKCa intermediate conductance Ca 2+ -activated K +
  • KSCa small conductance Ca 2+ -activated K +
  • Omega-3 fatty acids have been shown to cause endothelium-dependent vasorelaxation in vitro in rat aortic rings and coronary artery rings by stimulating the endothelial formation of NO (Engler et al., 2000; Omura et al., 2001).
  • NO endothelium-dependent vasorelaxation
  • the signal transduction pathway leading to eNOS activation remains poorly studied.
  • little information is currently available regarding the optimal ratio of EPA:DHA for the activation of eNOS. Therefore, the following experiments were carried out to characterize the fish oil-induced activation of eNOS in isolated blood vessels and cultured endothelial cells.
  • the initial experiment was designed to determine the ability of omega-3 fatty acids (EPA, DHA and different ratios of EPA:DHA) to cause endothelium-dependent relaxations in rings of porcine coronary arteries, thereby enabling the characterization of the role of NO and EDHF in endothelium-dependent relaxation and identification of the signal transduction pathway involved.
  • omega-3 fatty acids EPA, DHA and different ratios of EPA:DHA
  • Rings with or without endothelium were suspended in organ baths containing Krebs bicarbonate solution (composition in mM: NaCl 118.0, KC1 4.7, CaCl 2 2.5, MgS0 4 1.2, NaHC0 3 23.0; KH 2 P0 4 1.2 and glucose 11.0, pH 7.4, 37°C) oxygenated with a mixture of 95% 0 2 and 5% C0 2 .
  • Krebs bicarbonate solution composition in mM: NaCl 118.0, KC1 4.7, CaCl 2 2.5, MgS0 4 1.2, NaHC0 3 23.0; KH 2 P0 4 1.2 and glucose 11.0, pH 7.4, 37°C
  • ⁇ -nitro-L-arginine L-NA, 300 ⁇
  • NOS NO synthase
  • TRAM 34 100 nM
  • apamin 100 nM
  • IKCa and SKCa Ca 2+ -activated potassium channels
  • Pig coronary artery endothelial cells were harvested, cleaned with phosphate buffered saline solution (PBS) without calcium to remove any residual blood. Endothelial cells were isolated by collagenase (type I, Worthington, 1 mg/ml, 14 min at 37°C) and cultured in medium MCDB131 (Invitrogen) supplemented with 15% v/v fetal calf serum, 2 mM glutamine, 100 U/mL penicillin, 100 U/mL streptomycin and 250 mg/ml fungizone (Sigma, St Louis, MO) at 37°C in 5% C0 2 . All experiments were performed with confluent endothelial cells used at first passage. Endothelial cells were exposed to MCDB131 with 0.1% v/v fetal calf serum 5 h before treatment with different substances.
  • PBS phosphate buffered saline solution
  • endothelial cells were rinsed twice with PBS and lysed with extraction buffer (composition in mM: Tris / HC1 20, pH 7.5 (QBiogene), NaCl 150, Na 3 V0 4 1, Na P 2 0 7 10, NaF 20, okadaic acid 0.01 (Sigma), protease inhibitors (Complete Roche) and 1% Triton X-100). 25 ⁇ g of total proteins were separated on SDS- polyacrylamide (Sigma 8%) at 100 V for 2 h. Separated proteins were transferred onto a polyvinylidene fluoride membrane (Amersham) by electrophoresis at 100 V for 2 h.
  • extraction buffer composition in mM: Tris / HC1 20, pH 7.5 (QBiogene), NaCl 150, Na 3 V0 4 1, Na P 2 0 7 10, NaF 20, okadaic acid 0.01 (Sigma), protease inhibitors (Complete Roche) and 1% Triton X-100. 25
  • membranes were blocked with blocking buffer containing 3% bovine serum albumin in TBS-T (Tris-buffered saline solution, Biorad, containing 0.1% Tween 20, Sigma) for 1 h.
  • TBS-T Tris-buffered saline solution, Biorad, containing 0.1% Tween 20, Sigma
  • membranes were incubated in TBS-T containing the respective primary antibodies (p-eNOS Ser 1177, p-eNOS Thr 495 and p-Akt Ser 473 (dilution
  • Bonferoni post-hoc test A P value of ⁇ 0.05 is considered statistically significant.
  • the omega-3 fatty acid preparation EPA:DHA 1 : 1 induced concentration- dependent relaxations of coronary artery rings with endothelium whereas only small relaxations were obtained in those without endothelium contracted with U46619 ( Figure 4).
  • the relaxations to EPA:DHA 1 :1 was observed at volumes greater than 0.01 % v/v and they reached about 75% at 0.4 % v/v ( Figure 4).
  • the omega-3 fatty acid preparation EPA:DHA 6: 1 also induced endothelium-dependent relaxations which were more potent than those induced by EPA:DHA 1 : 1 ( Figure 4).
  • omega-3 fatty acid preparation EPA:DHA 6:1 induces endothelium-dependent relaxations involving both NO and EDHF.
  • Omega-3 in % signifies total omega-3 in % of total fatty acids as EE (ethyl esters)
  • Indomethacin is an inhibitor of COX-1 and thus will prevent the formation of vasorelaxing prostanoids.
  • the magnitude of the endothelium-dependent relaxation is dependent on the purity of the formulation ( Figure 9) and on the EPA:DHA ratio ( Figure 4).
  • the EPA:DHA 6: 1 formulation caused similar endothelium-dependent relaxation as the OTC Omega-3 product TETESEPTTM with an omega-3 purity (as defined above) of 22.2 % as compared to that of the EPA:DHA 6: 1 formulation of 75.1 % and was much more effective than the other OTC Omega-3 s tested (ABTEI LACHSOLTM 1300, DOPPELHERZTM, SCHAEBENSTM and OPTISANATM ( Figure 11 A).
  • TETESEPTTM has a more than fivefold higher vitamin E content than that of the
  • omega-3 fatty acid preparations are potent endothelium-dependent vasodilators and that this effect is dependent on the ratio and the omega-3 purity of EPA and DHA within the capsule. They further suggest that omega-3 fatty acids activate eNOS via a redox-sensitive PI3 -kinase/ Akt pathway leading to changes in the phosphorylation level of eNOS as illustrated in Figure 14.
  • All patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition et un procédé de traitement utilisant une combinaison d'inhibiteurs de l'absorption du cholestérol hypolipémiants, par exemple, des azétidinones, avec des mélanges d'une formulation d'acides gras oméga 3 contenant environ 90 % en poids ou plus d'acides gras oméga 3 y compris une combinaison d'acide eicosapentaénoïque (EPA), d'acide docosapentaénoïque (DPA) et d'acide docosahexaénoïque (DHA) en un rapport en poids d'EPA/DHA de 5,7 à 6,3, la somme de l'EPA, du DHA et du DPA représentant environ 82 % en poids de la formulation totale et environ 92 % de la teneur en acide gras oméga 3 totale de la composition. L'EPA + le DHA constituent environ 80 % de la formulation totale et environ 89 % de la teneur en acide gras oméga 3 de la composition. La formulation peut en outre contenir des quantités spécifiques d'acide arachidonique (AA) et d'acides gras oméga 3 ayant 18 atomes de carbone, y compris un ou plusieurs de l'acide stéaridonique (SDA) et de l'acide alpha-linolénique (ALA). La présente invention enseigne en outre des procédés d'administration de ces combinaisons, et concerne des unités posologiques de ces combinaisons pour la réduction des facteurs de risque de maladies cardiovasculaires.
PCT/US2012/025003 2011-02-16 2012-02-14 Inhibiteur de l'absorption du cholestérol (azétidinone) et acides gras oméga 3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction des événements cardiovasculaires WO2012112511A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP12705588.7A EP2675442A1 (fr) 2011-02-16 2012-02-14 Inhibiteur de l'absorption du cholestérol (azétidinone) et acides gras oméga 3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction des événements cardiovasculaires
CA2827555A CA2827555A1 (fr) 2011-02-16 2012-02-14 Inhibiteur de l'absorption du cholesterol (azetidinone) et acides gras omega 3 (epa, dha, dpa) pour la reduction du cholesterol et pour la reduction des evenements cardiovasculaires
JP2013554537A JP2014505729A (ja) 2011-02-16 2012-02-14 コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ）
US13/584,403 US8952000B2 (en) 2011-02-16 2012-08-13 Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
PCT/US2012/051103 WO2013122624A1 (fr) 2012-02-14 2012-08-16 Inhibiteur d'absorption du cholestérol à base d'azétidinone (ézétimibe) et acides gras oméga-3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction d'événements cardiovasculaires
EP12753303.2A EP2814476A1 (fr) 2012-02-14 2012-08-16 Inhibiteur d'absorption du cholestérol à base d'azétidinone (ézétimibe) et acides gras oméga-3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction d'événements cardiovasculaires

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161457268P 2011-02-16 2011-02-16
US61/457,268 2011-02-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/584,403 Continuation-In-Part US8952000B2 (en) 2011-02-16 2012-08-13 Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events

Publications (1)

Publication Number Publication Date
WO2012112511A1 true WO2012112511A1 (fr) 2012-08-23

Family

ID=45755568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/025003 WO2012112511A1 (fr) 2011-02-16 2012-02-14 Inhibiteur de l'absorption du cholestérol (azétidinone) et acides gras oméga 3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction des événements cardiovasculaires

Country Status (4)

Country Link
EP (1) EP2675442A1 (fr)
JP (1) JP2014505729A (fr)
CA (1) CA2827555A1 (fr)
WO (1) WO2012112511A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089511A3 (fr) * 2012-12-06 2014-07-31 Matinas Biopharma, Inc. Procédés d'administration de compositions comprenant de l'acide docosapentaénoïque
EP2800563A1 (fr) * 2012-01-06 2014-11-12 Omthera Pharmaceuticals Inc. Compositions enrichies en dpa d'acides gras oméga-3 polyinsaturés sous forme d'acide libre
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862873A1 (fr) * 2003-12-01 2005-06-03 Pf Medicament Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
WO2007011886A2 (fr) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Traitement au moyen d'inhibiteurs d'absorption de cholesterol a base d'azetidinone et d'acide gras omega-3 et produit de combinaison de ceux-ci
US20070141138A1 (en) * 2005-12-20 2007-06-21 Cenestra Llc Omega 3 fatty acid formulations
EP1800675A1 (fr) * 2005-12-23 2007-06-27 Nutricia N.V. Composition comprenant des acides gras polyinsaturés, des protéines et du manganèse et/ou du molybdène, pour améliorer la composition des mebranes cellulaires
WO2010103402A1 (fr) * 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprenant un mélange oléagineux à base d'acides gras comportant de l'epa et du dha sous forme d'acide libre et un tensioactif, et procédés et utilisations associés

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2417712C2 (ru) * 2005-12-23 2011-05-10 Н.В. Нютрисиа Питательная композиция для младенцев, предназначенная для предупреждения ожирения

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862873A1 (fr) * 2003-12-01 2005-06-03 Pf Medicament Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
WO2007011886A2 (fr) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Traitement au moyen d'inhibiteurs d'absorption de cholesterol a base d'azetidinone et d'acide gras omega-3 et produit de combinaison de ceux-ci
US20070141138A1 (en) * 2005-12-20 2007-06-21 Cenestra Llc Omega 3 fatty acid formulations
EP1800675A1 (fr) * 2005-12-23 2007-06-27 Nutricia N.V. Composition comprenant des acides gras polyinsaturés, des protéines et du manganèse et/ou du molybdène, pour améliorer la composition des mebranes cellulaires
WO2010103402A1 (fr) * 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprenant un mélange oléagineux à base d'acides gras comportant de l'epa et du dha sous forme d'acide libre et un tensioactif, et procédés et utilisations associés

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "OmegaBrite", CONSUMERLAB.COM, 25 May 2008 (2008-05-25), XP055022752, Retrieved from the Internet <URL:http://www.consumerlab.com/results/ob.asp> [retrieved on 20120323] *
BIOORG. MED. CHEM., vol. 7, no. 10, 1999, pages 2199 - 202
N ENGL J MED, vol. 346, no. 15, 11 April 2002 (2002-04-11), pages 1113 - 1118
NATURE CHEMICAL BIOLOGY, vol. 6, June 2010 (2010-06-01), pages 401 - 402
ROSENBLUM, S. B. ET AL., J. MED. CHEM., vol. 41, no. 6, 1998, pages 973 - 80
WU ET AL., J NUTR., vol. 135, 2005, pages 1847 - 1853
ZHAO ET AL., AM J CLIN NUTR, vol. 85, 2007, pages 385 - 91

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2800563A1 (fr) * 2012-01-06 2014-11-12 Omthera Pharmaceuticals Inc. Compositions enrichies en dpa d'acides gras oméga-3 polyinsaturés sous forme d'acide libre
US9050309B2 (en) 2012-01-06 2015-06-09 Omthera Pharmaceuticals, Inc. DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US9050308B2 (en) 2012-01-06 2015-06-09 Omthera Pharmaceuticals, Inc. DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EP2800563A4 (fr) * 2012-01-06 2015-06-17 Omthera Pharmaceuticals Inc Compositions enrichies en dpa d'acides gras oméga-3 polyinsaturés sous forme d'acide libre
EP3348262A1 (fr) * 2012-01-06 2018-07-18 Omthera Pharmaceuticals Inc. Procédés pour la préparation des compositions enrichies en dpa d'acides gras oméga-3 polyinsaturés sous forme d'acide libre
US10117844B2 (en) 2012-01-06 2018-11-06 Omthera Pharmaceuticals, Inc. DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
WO2014089511A3 (fr) * 2012-12-06 2014-07-31 Matinas Biopharma, Inc. Procédés d'administration de compositions comprenant de l'acide docosapentaénoïque

Also Published As

Publication number Publication date
EP2675442A1 (fr) 2013-12-25
CA2827555A1 (fr) 2012-08-23
JP2014505729A (ja) 2014-03-06

Similar Documents

Publication Publication Date Title
EP2675445A1 (fr) Statine et acides gras oméga-3 (epa, dha et dpa) utilisés dans les maladies cardiovasculaires
EP2675443A1 (fr) Test diagnostique des taux d&#39;acides gras oméga-3 pour la prise en charge alimentaire des patients atteints d&#39;une maladie cardiovasculaire
US20150119414A1 (en) Statin and omega 3 fatty acids for reduction of apolipoprotein-b levels
US20150224075A1 (en) Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US20150246012A1 (en) Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagnostic assay for the dietary management of cardiovascular patients with cardiovascular disease (cvd) who are deficient in blood epa and dha levels
US8715648B2 (en) Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
WO2012112511A1 (fr) Inhibiteur de l&#39;absorption du cholestérol (azétidinone) et acides gras oméga 3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction des événements cardiovasculaires
WO2012112527A1 (fr) Préparations à base d&#39;oméga-3 comprenant epa, dha et dpa pour le traitement des facteurs de risque dans la maladie cardiovasculaire
EP2675444A1 (fr) Préparations comprenant des acides gras oméga-3 et un agent anti-obésité pour la réduction du poids corporel chez les patients atteints d&#39;une maladie cardiovasculaire et chez les diabétiques
US20060009486A1 (en) Composition and method for treatment and prevention of coronary artery disease
JP2009544701A (ja) オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
US8952000B2 (en) Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9248138B2 (en) Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids
WO2015106177A1 (fr) Procédé et composition de stabilisation de plaques vulnerables à l&#39;aide d&#39;une combinaison composée d&#39;une statine et d&#39;acides gras omega 3
US20150272920A1 (en) Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12705588

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2827555

Country of ref document: CA

Ref document number: 2013554537

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012705588

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012705588

Country of ref document: EP